AR036813A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
AR036813A1
AR036813A1 ARP020103852A ARP020103852A AR036813A1 AR 036813 A1 AR036813 A1 AR 036813A1 AR P020103852 A ARP020103852 A AR P020103852A AR P020103852 A ARP020103852 A AR P020103852A AR 036813 A1 AR036813 A1 AR 036813A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
mycophenolic acid
mycophenolate salt
dose form
solid dose
Prior art date
Application number
ARP020103852A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9924043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR036813(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR036813A1 publication Critical patent/AR036813A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forma de dosis sólida, por ejemplo, una tableta, que comprende ácido micofenólico o una sal de micofenolato y un proceso para su producción. Reivindicación 1: Una forma de dosis sólida que comprende una cantidad farmacológicamente efectiva de ácido micofenólico o sal de micofenolato, en donde el ácido micofenólico o la sal de micofenolato está presente en una cantidad desde alrededor del 20% hasta alrededor del 95% en peso con base en el peso total de la forma de dosis sólida.
ARP020103852A 2001-10-17 2002-10-15 Composiciones farmaceuticas AR036813A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124953.1A GB0124953D0 (en) 2001-10-17 2001-10-17 Organic Compounds

Publications (1)

Publication Number Publication Date
AR036813A1 true AR036813A1 (es) 2004-10-06

Family

ID=9924043

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020103852A AR036813A1 (es) 2001-10-17 2002-10-15 Composiciones farmaceuticas
ARP120101574A AR085778A2 (es) 2001-10-17 2012-05-04 Forma de dosis solida enterica revestida, que comprende acido micofenolico o sal micofenolato

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP120101574A AR085778A2 (es) 2001-10-17 2012-05-04 Forma de dosis solida enterica revestida, que comprende acido micofenolico o sal micofenolato

Country Status (32)

Country Link
US (3) US20050013859A1 (es)
EP (1) EP1438040B2 (es)
JP (2) JP2005508959A (es)
KR (1) KR100671367B1 (es)
CN (1) CN1310640C (es)
AR (2) AR036813A1 (es)
AT (1) ATE374023T1 (es)
AU (1) AU2002338897B2 (es)
BR (1) BR0213355A (es)
CA (1) CA2460574A1 (es)
CO (1) CO5390076A1 (es)
CY (1) CY1107841T1 (es)
DE (1) DE60222687T3 (es)
DK (1) DK1438040T4 (es)
EC (2) ECSP024341A (es)
ES (1) ES2292819T5 (es)
GB (1) GB0124953D0 (es)
HK (1) HK1067861A1 (es)
HU (1) HU231114B1 (es)
IL (2) IL160968A0 (es)
MX (1) MXPA04003636A (es)
MY (1) MY139206A (es)
NO (1) NO341804B1 (es)
NZ (1) NZ532280A (es)
PE (1) PE20030476A1 (es)
PL (2) PL234541B1 (es)
PT (1) PT1438040E (es)
RU (2) RU2338528C2 (es)
SI (1) SI1438040T2 (es)
TW (1) TWI333861B (es)
WO (1) WO2003032978A1 (es)
ZA (1) ZA200401977B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7439373B2 (en) * 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
AU2006297130B2 (en) * 2005-09-30 2009-12-24 Novartis Ag DPP IV inhibitor for use in the treatment of autoimmune diseases and graft rejection
ES2403167T3 (es) * 2005-12-21 2013-05-14 Basf Se Polivinilpirrolidona entrelazada finamente dividida como agente desintegrador de tabletas
AU2007214784A1 (en) * 2006-02-13 2007-08-23 Novartis Ag High dosage of mycophenolic acid (MPA)
WO2008148742A2 (de) 2007-06-06 2008-12-11 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
JP2010529071A (ja) 2007-06-06 2010-08-26 ビーエーエスエフ ソシエタス・ヨーロピア 速崩性錠剤製造のための医薬製剤
BRPI0816231A2 (pt) * 2007-08-13 2015-06-16 Panacea Biotec Ltd Composições de liberação prolongada compreendendo micofenolato de sódio e seus processos
EA201071035A1 (ru) * 2008-03-05 2011-04-29 Панацеа Биотек Лимитед Фармацевтические композиции модифицированного высвобождения, содержащие микофенолат, и способ их получения
WO2010004435A2 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
EA201270544A1 (ru) * 2009-10-13 2012-09-28 Тева Фармасьютикал Индастриз Лтд. Композиции с отсроченным высвобождением
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
CN102793658A (zh) * 2012-08-23 2012-11-28 无锡福祈制药有限公司 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片
CN103845323B (zh) * 2012-11-30 2018-02-02 重庆华邦制药有限公司 麦考酚酸及其盐肠溶制剂和制备方法
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
CN106727403A (zh) * 2017-01-03 2017-05-31 无锡福祈制药有限公司 一种麦考酚钠肠溶片及其制备方法
AU2018236225B2 (en) * 2017-03-13 2023-11-30 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
BR112020024643A2 (pt) 2018-06-06 2021-03-02 Metavant Sciences Gmbh método de tratamento de pré-diabetes ou diabetes mellitus tipo 1 ou tipo 2, método de melhoria do controle glicêmico em um sujeito tendo pré-diabetes ou diabetes tipo 1 ou tipo 2, imeglimina para uso em um método para tratamento de pré-diabetes ou diabetes mellitus tipo 1 ou tipo 2 de um sujeito, imeglimina para uso em um método para melhoria do controle glicêmico em um sujeito tendo pré-diabetes ou diabetes tipo 1 ou tipo 2, uso de imeglimina para a fabricação de um medicamento para o tratamento de um sujeito tendo pré-diabetes ou diabetes mellitus tipo 1 ou tipo 2 e uso de imeglimina para a fabricação de um medicamento para melhoria do controle glicêmico em um sujeito tendo pré-diabetes ou diabetes tipo 1 ou tipo 2
BR112020025112A2 (pt) 2018-06-14 2021-03-23 Poxel comprimido revestido por película e processo para a fabricação do comprimido revestido por película
RU2723255C2 (ru) * 2018-11-14 2020-06-09 Общество с ограниченной ответственностью "Изварино Фарма" Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы
WO2022162088A2 (en) * 2021-01-28 2022-08-04 Priothera Sas Methods of treatment with s1p receptor modulators
EP4346790A1 (en) * 2021-05-26 2024-04-10 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN117442580B (zh) * 2023-12-21 2024-04-05 泊诺(天津)创新医药研究有限公司 一种高生物利用度麦考酚钠肠溶片及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1157100A (en) † 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
JPS56127093A (en) * 1980-03-10 1981-10-05 Ajinomoto Co Inc Preparation of mycophenolic acid
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US5177072A (en) * 1987-01-30 1993-01-05 Syntex (U.S.A.) Inc. Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives
US4748173A (en) * 1987-01-30 1988-05-31 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof and pharmaceutical compositions
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
AU3178293A (en) * 1992-11-24 1994-06-22 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
WO1994012184A1 (en) * 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
BR9405836A (pt) * 1993-02-26 1996-01-16 Procter & Gamble Forma de dosagem de bisacodil
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ES2248793T3 (es) * 1993-10-01 2006-03-16 Roche Palo Alto Llc Suspensiones orales de alta dosis de mofetil micofenolato.
AU7961094A (en) * 1993-10-19 1995-05-08 Procter & Gamble Company, The Picosulphate dosage form
US5514663A (en) * 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
ATE474590T1 (de) * 1999-05-10 2010-08-15 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
HUP9903226A2 (en) * 1999-09-23 2002-08-28 Gyogyszerki Process for producing mycophenolic acid and derivatives thereof
AU2000233225A1 (en) * 2000-02-29 2001-09-12 Biocon India Limited Manufacture and purification of mycophenolic acid
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PL415001A1 (pl) 2016-02-29
MY139206A (en) 2009-08-28
HU231114B1 (hu) 2020-09-28
PE20030476A1 (es) 2003-07-30
DE60222687T2 (de) 2008-07-17
SI1438040T1 (sl) 2008-04-30
EP1438040B1 (en) 2007-09-26
JP2005508959A (ja) 2005-04-07
ATE374023T1 (de) 2007-10-15
NO341804B1 (no) 2018-01-22
IL160968A (en) 2016-04-21
CN1564684A (zh) 2005-01-12
ECSP024342A (es) 2003-03-10
PT1438040E (pt) 2008-01-02
IL160968A0 (en) 2004-08-31
HUP0600451A2 (en) 2006-09-28
US20100210717A1 (en) 2010-08-19
CA2460574A1 (en) 2003-04-24
NO20041785L (no) 2004-05-03
PL367738A1 (en) 2005-03-07
US20120237601A1 (en) 2012-09-20
AR085778A2 (es) 2013-10-30
JP2009137996A (ja) 2009-06-25
CN1310640C (zh) 2007-04-18
EP1438040B2 (en) 2019-10-16
CY1107841T1 (el) 2013-06-19
MXPA04003636A (es) 2004-07-27
CO5390076A1 (es) 2004-04-30
TWI333861B (en) 2010-12-01
DK1438040T4 (da) 2020-01-27
SI1438040T2 (sl) 2020-02-28
HK1067861A1 (en) 2005-04-22
EP1438040A1 (en) 2004-07-21
ES2292819T3 (es) 2008-03-16
RU2381026C2 (ru) 2010-02-10
NZ532280A (en) 2007-05-31
US20050013859A1 (en) 2005-01-20
DK1438040T3 (da) 2008-02-04
ES2292819T5 (es) 2020-05-29
WO2003032978A1 (en) 2003-04-24
DE60222687D1 (de) 2007-11-08
KR100671367B1 (ko) 2007-01-19
GB0124953D0 (en) 2001-12-05
KR20050037409A (ko) 2005-04-21
RU2004115332A (ru) 2005-04-20
DE60222687T3 (de) 2020-03-05
PL234541B1 (pl) 2020-03-31
RU2338528C2 (ru) 2008-11-20
BR0213355A (pt) 2006-05-23
ECSP024341A (es) 2003-12-01
ZA200401977B (en) 2006-05-31
AU2002338897B2 (en) 2006-10-19
RU2007130786A (ru) 2009-02-20

Similar Documents

Publication Publication Date Title
AR036813A1 (es) Composiciones farmaceuticas
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
AR084101A2 (es) Comprimido de carga de droga alta y proceso para su preparacion
GT200100183A (es) Derivados de quinolina y quinazolina.
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
BRPI0508833A (pt) formulações galênicas de compostos orgánicos
SV1999000049A (es) Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
BRPI0518266B8 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
MX2007008227A (es) Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos.
AR033688A1 (es) Composicion parenteral reconstituible
CO6220902A2 (es) Formulacion en polvo del valganciclovir
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
BR0211198A (pt) Composições farmacêuticas e seu uso
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
ECSP088408A (es) Composiciones farmacéuticas que comprenden combinaciones de analgésicos y anticonvulsivantes para el tratamiento del dolor agudo y crónico
UY27018A1 (es) Derivados de la pirimidina
CY1111129T1 (el) Στερεη φαρμακευτικη ενωση που περιεχει τελιθρομυκινη
AR080541A1 (es) Tratamiento para la endometriosis
BR112023000798A2 (pt) Composições farmacêuticas compreendendo venglustat
AR016017A1 (es) Formulaciones farmaceuticas y proceso para su preparacion

Legal Events

Date Code Title Description
FC Refusal